Literature DB >> 10921706

Reduction of heparin dose is not beneficial to platelet function.

T Nakajima1, K Kawazoe, K Ishibashi, Y Kubota, T Sasaki, H Izumoto, T Nitatori.   

Abstract

BACKGROUND: To clarify the effects of the reduction of heparin dose on platelets, we conducted a prospective trial on patients undergoing cardiopulmonary bypass.
METHODS: Twenty-three patients undergoing coronary artery bypass grafting were studied. The systemic heparin dose was 300 IU/kg in the control group (n = 11) and 200 IU/kg in the low-dose group (n = 12). Heparin-coated cardiopulmonary bypass equipment was used for both the groups. Platelet counts, beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) concentrations were measured and the arterial filters in the circuits were observed by electron microscopy.
RESULTS: Platelet counts were higher in the low-dose group than in the control group (p < 0.01). No significant differences were found in the platelet release reaction (beta-TG and PF4). Electron microscopy demonstrated that cell adhesion on the arterial filters in the control group was significantly more marked than in the low-dose group (p < 0.01) and that most of the cells on the filters were neutrophils.
CONCLUSIONS: We conclude that the reduction of heparin dose with the use of heparin-coated equipment reduces platelet loss, but does not suppress the platelet release reaction. Furthermore, the reduction of heparin dose reduces adherence of leukocytes to the filter surface.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10921706     DOI: 10.1016/s0003-4975(00)01389-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

Review 1.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.